Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285809503> ?p ?o ?g. }
- W4285809503 endingPage "453" @default.
- W4285809503 startingPage "444" @default.
- W4285809503 abstract "Effective consolidative chemoradiation (CRT) regimens are lacking. In this phase 1 trial, we evaluated the safety and efficacy of nab-paclitaxel, capecitabine, and radiation therapy after induction chemotherapy in patients with locally advanced and borderline-resectable pancreatic cancer (LAPC and BRPC). Also, we evaluated a computed tomography (CT)-based biomarker of response.Eligible patients had pathologically confirmed pancreatic ductal adenocarcinoma, underwent computed tomography-imaging, received a diagnosis of LAPC or BRPC, and received induction chemotherapy. Standard 3 + 3 study design was used, with 3 escalating nab-paclitaxel dose levels (50, 75, and 100 mg/m2) with concurrent capecitabine and RT in cohort sizes of 3 starting at the lowest dose. Dose limiting toxicity was defined as grade 3 or higher toxicity. Patients were restaged 4 to 6 weeks post-CRT completion, and surgical resection was offered to those with stable/responsive disease. We scored the tumor interface response (IR) postchemotherapy and post-CRT into type I (remained/became more defined) and type II (became less defined). Overall survival (OS) and progression-free survival (PFS) from time of CRT were estimated using Kaplan-Meier method. P ≤ .05 was considered significant.Twenty-three patients started and finished on protocol (LAPC = 14, BRPC = 9). No grade 3 and 4 toxicities were reported in level 1 (n = 3) or level 2 (n = 3) initial groups. Two patients in the initial level 3 group developed dose limiting toxicity, establishing level 2 dose as the maximal tolerated dose. Level 2 group was expanded for additional 15 patients (for a total of 23 on trial), 5 of whom developed grade 3 toxicities. Seven patients underwent surgical resection. Median OS and PFS were 21.2 and 8.1 months, respectively. Type I IR was associated with better OS (P = .004) and PFS (P = .03) compared with type II IR.We established the maximum tolerated dose for nab-paclitaxel in a consolidative CRT regimen for pancreatic ductal adenocarcinoma. Preliminary efficacy results warrant phase 2 trial evaluation. IR may be used for personalized treatment." @default.
- W4285809503 created "2022-07-19" @default.
- W4285809503 creator A5002983175 @default.
- W4285809503 creator A5003827387 @default.
- W4285809503 creator A5007461029 @default.
- W4285809503 creator A5011546832 @default.
- W4285809503 creator A5016694714 @default.
- W4285809503 creator A5022491856 @default.
- W4285809503 creator A5026186757 @default.
- W4285809503 creator A5026500137 @default.
- W4285809503 creator A5026913056 @default.
- W4285809503 creator A5028750813 @default.
- W4285809503 creator A5035371911 @default.
- W4285809503 creator A5046059508 @default.
- W4285809503 creator A5046135731 @default.
- W4285809503 creator A5052650376 @default.
- W4285809503 creator A5054771911 @default.
- W4285809503 creator A5059256779 @default.
- W4285809503 creator A5061830380 @default.
- W4285809503 creator A5067325396 @default.
- W4285809503 creator A5070664424 @default.
- W4285809503 creator A5071185138 @default.
- W4285809503 creator A5072186742 @default.
- W4285809503 creator A5078455132 @default.
- W4285809503 creator A5079075847 @default.
- W4285809503 creator A5082283107 @default.
- W4285809503 creator A5082668053 @default.
- W4285809503 creator A5084349853 @default.
- W4285809503 creator A5084420501 @default.
- W4285809503 creator A5087201995 @default.
- W4285809503 creator A5088853428 @default.
- W4285809503 creator A5090991465 @default.
- W4285809503 date "2022-11-01" @default.
- W4285809503 modified "2023-09-30" @default.
- W4285809503 title "Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation" @default.
- W4285809503 cites W1940632416 @default.
- W4285809503 cites W1968812902 @default.
- W4285809503 cites W1975153720 @default.
- W4285809503 cites W1978651988 @default.
- W4285809503 cites W1991525295 @default.
- W4285809503 cites W1993151948 @default.
- W4285809503 cites W2006210070 @default.
- W4285809503 cites W2019607817 @default.
- W4285809503 cites W2054383376 @default.
- W4285809503 cites W2103711657 @default.
- W4285809503 cites W2107965719 @default.
- W4285809503 cites W2117602118 @default.
- W4285809503 cites W2118797060 @default.
- W4285809503 cites W2144536924 @default.
- W4285809503 cites W2153539090 @default.
- W4285809503 cites W2165480504 @default.
- W4285809503 cites W2168896006 @default.
- W4285809503 cites W2170202192 @default.
- W4285809503 cites W2171500698 @default.
- W4285809503 cites W2172089182 @default.
- W4285809503 cites W2196287118 @default.
- W4285809503 cites W2271971696 @default.
- W4285809503 cites W2346921980 @default.
- W4285809503 cites W2542336063 @default.
- W4285809503 cites W2595551151 @default.
- W4285809503 cites W2626829286 @default.
- W4285809503 cites W2732556476 @default.
- W4285809503 cites W2791078127 @default.
- W4285809503 cites W2801301689 @default.
- W4285809503 cites W2888094806 @default.
- W4285809503 cites W2960253622 @default.
- W4285809503 cites W2987032924 @default.
- W4285809503 cites W2999417355 @default.
- W4285809503 cites W3000487074 @default.
- W4285809503 cites W3005912285 @default.
- W4285809503 cites W3094538766 @default.
- W4285809503 cites W3094632031 @default.
- W4285809503 cites W3122184502 @default.
- W4285809503 cites W3135350757 @default.
- W4285809503 cites W3184455560 @default.
- W4285809503 doi "https://doi.org/10.1016/j.ijrobp.2022.06.089" @default.
- W4285809503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35863672" @default.
- W4285809503 hasPublicationYear "2022" @default.
- W4285809503 type Work @default.
- W4285809503 citedByCount "3" @default.
- W4285809503 countsByYear W42858095032023 @default.
- W4285809503 crossrefType "journal-article" @default.
- W4285809503 hasAuthorship W4285809503A5002983175 @default.
- W4285809503 hasAuthorship W4285809503A5003827387 @default.
- W4285809503 hasAuthorship W4285809503A5007461029 @default.
- W4285809503 hasAuthorship W4285809503A5011546832 @default.
- W4285809503 hasAuthorship W4285809503A5016694714 @default.
- W4285809503 hasAuthorship W4285809503A5022491856 @default.
- W4285809503 hasAuthorship W4285809503A5026186757 @default.
- W4285809503 hasAuthorship W4285809503A5026500137 @default.
- W4285809503 hasAuthorship W4285809503A5026913056 @default.
- W4285809503 hasAuthorship W4285809503A5028750813 @default.
- W4285809503 hasAuthorship W4285809503A5035371911 @default.
- W4285809503 hasAuthorship W4285809503A5046059508 @default.
- W4285809503 hasAuthorship W4285809503A5046135731 @default.
- W4285809503 hasAuthorship W4285809503A5052650376 @default.
- W4285809503 hasAuthorship W4285809503A5054771911 @default.
- W4285809503 hasAuthorship W4285809503A5059256779 @default.